Deep quantum modelling: Shifting the drug-discovery paradigm
Adityo Prakash, CEO of Verseon, introduces a new mathematical approach to computing molecular interactions. The objective of small-molecule drug discovery is to find binders to target proteins involved in disease processes. However, the discovery and development of novel small-molecule therapeutics remains one of the most resource-intensive endeavors… Read More